First Case of Parkinsonian-Pyramidal Syndrome Associated with a TBK1 Mutation

Diego Santos-García*, Jelena Pozojevic, Teresa de Deus Fonticoba, Mónica Kurtis, Josep Gamez, Christine Klein, Mariana H.G. Monje, Ana Westenberger

*Korrespondierende/r Autor/-in für diese Arbeit
OriginalspracheEnglisch
ZeitschriftMovement Disorders
ISSN0885-3185
DOIs
PublikationsstatusVeröffentlicht - 02.2021

Fördermittel

We thank the patient for taking part in this study. A.W. and C. K. are supported by the German Research Foundation (Deutsche Forschungsgemeinschaft) Research Unit FOR2488. D.S‐G. reports employment with SERGAS, advisory board of Sense4care, and honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, and Teva. J.P. reports employment with University Medical Center Schleswig‐Holstein, Campus Lübeck, Germany. T.D.F. has nothing to report. M.K. reports employment with Neurologia Aplicada S.A.; honoraria for educational talks by the MDS, Bial and Eisai; and participation in a Michael J Fox grant. J.G. reports employment with GMA Clinic. C.K. is a medical consultant to CENTOGENE GmbH for genetic testing for movement disorders (except parkinsonism) and dementia; reports employment University Medical Center Schleswig‐Holstein, Campus Lübeck, and University of Lübeck, Germany; reports the Scientific Advisory Board of the Else Kroener Fresenius Foundation; royalties from Oxford University Press; grants from the Movement Disorder Society, Michael J. Fox Foundation (MJFF), BMBF, and the European Commission; and intramural funds from the University of Lübeck. M.H.G.M. reports employment with the Autonomous University of Madrid and HM‐Puerta del Sur University Hospital and honoraria for educational presentations by Novartis. A.W. reports medical writing at CENTOGENE GmbH, employment with University Medical Center Schleswig‐Holstein, Campus Lübeck, Germany; honoraria from CENTOGENE GmbH; and grants from the The German Research Foundation.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

  • Querschnittsbereich: Medizinische Genetik

Zitieren